Allopurinol
规格
315-30-0CAS 号
206-250-9EC 号
1,5-dihydropyrazolo[5,4-d]pyrimidin-4-oneIUPAC 名称
C5H4N4O化学式
136.11 g/mol分子量
allopurinol; 315-30-0; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol; Zyloric; Suspendol; Takanarumin; Allopur; Bloxanth; Uriprim; Xanturat; Urbol; Ketobun-A; Nektrohan; Adenock; Aluline; Dabrosin; Urobenyl; 4-Hydroxypyrazolo[3,4-d]pyrimidine; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; Allopurinol(I); Allopurinolum; 4-HPP; Alopurinol; 1H-Pyrazolo(3,4-d)pyrimidin-4-ol; 4-Hydroxypyrazolopyrimidine; NSC-1390; 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine; 4-Hydroxy-3,4-pyrazolopyrimidine; Sigapurol; 4-Hydroxypyrazolo(3,4-d)pyrimidine; 4-Hydroxypyrazolyl(3,4-d)pyrimidine; 4H-Pyrazolo(3,4-d)pyrimidin-4-one; 4'-Hydroxypyrazolol(3,4-d)pyrimidine; BW 56-158; AL-100; BW-56-158; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one; 1,5-Dihydropyrazolo[3,4-d]pyrimidin-4-one; 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one; Uricto; DTXSID4022573; CHEBI:40279; 4H-Pyrazolo(3,4-d)pyrimidin-4-one, 1,5-dihydro-; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-; 1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one; 63CZ7GJN5I; Xanthomax-100; Xanthomax-300; NSC-101655; Aluline 100; Aluline 300; Hamarin 100; Hamarin 300; Zyloric-300; NSC1390; 1H,2H,4H-pyrazolo[3,4-d]pyrimidin-4-one; NSC101655; BW-56158; 4-Hydroxy-1H-pyrazolo[3,4-d]pyrimidine; DTXCID502573; DUZALLO COMPONENT ALLOPURINOL; Milurite; Allohexan; 4-Hydroxypyrazolyl[3,4-d]pyrimidine; Pan Quimica; 4'-Hydroxypyrazolol[3,4-d]pyrimidine; 1,2-dihydropyrazolo(3,4-d)pyrimidin-4-one; 1,5-dihydropyrazolo(3,4-d)pyrimidin-4-one; 1H,2H,4H-pyrazolo(3,4-d)pyrimidin-4-one; allopurinolo; Zurinol; RefChem:54100; 4'-HPP; M04AA01; 1,5-Dihydro-4H-pyrazolo(3,4-d)pryimidin-4-one; 206-250-9; Zyloprim; Lopurin; Urosin; Atisuril; Epidropal; Uricemil; Anzief; Urolit; Anoprolin; Miniplanor; Ailural; Allozym; Alositol; Cosuric; Gichtex; Ledopur; Progout; Aloral; Apurol; Riball; 1H-Pyrazolo[3,4-d]pyrimidin-4(5H)-one; Ketanrift; Monarch; Hexanuret; Epuric; 180749-06-8; 180749-08-0; 73334-58-4; Dura Al; 1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one; 2H-Pyrazolo[3,4-d]pyrimidin-4-ol; Urtias 100; Alopurinol [INN-Spanish]; Allopurinolum [INN-Latin]; 1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one; 180749-09-1; 916980-04-6; MFCD00599413; Zyloprim (TN); 1H,4H,7H-pyrazolo[3,4-d]pyrimidin-4-one; B. W. 56-158; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,2-dihydro-; 180749-07-9; 184789-03-5; MLS000069453; SMR000059083; 291279-53-3; 1H,4H,5H-pyrazolo[3,4-d]pyrimidin-4-one; 4-Oxopyrazolo[3,4-d]pyrimidine; NCGC00015094-02; NCGC00094580-04; Uritas; 1,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-one; 1,7-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; 4H-pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro-; F3329-0375; NSC 1390; pyrazolo[5,4-d]pyrimidin-4-ol; 4H-Pyrazolo[3, 1,5-dihydro-; Ailurial; WLN: T56 BMN GN INJ FQ; CAS-315-30-0; CCRIS 626; NSC 101655; HSDB 3004; SR-05000001983; EINECS 206-250-9; UNII-63CZ7GJN5I; Allohexal;; ATH008; Allopurinol RS; Zyloprim;; 1H-Pyrazolo[3,4-d]pyrimidin-4-ol (9CI); Allopurinol CRS; Allosig;; Progout;; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,7-dihydro- (9CI); Xanthione oxidase; Prestwick_511; Allopurinol [USAN:USP:INN:BAN:JAN]; Allopurinol (Standard); Spectrum_000026; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,5-dihydro- (9CI); 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,7-dihydro- (9CI); Allopurinol - EP grade; ALLOPURINOL [MI]; Opera_ID_1680; Spectrum2_000098; Spectrum3_000289; Spectrum4_000135; Spectrum5_000768; ALLOPURINOL [INN]; ALLOPURINOL [JAN]; Lopac-A-8003; 1,4-d]pyrimidin-4-one; ALLOPURINOL [HSDB]; ALLOPURINOL [USAN]; Epitope ID:226980; A 8003; cid_2094; SCHEMBL4627; SCHEMBL4628; A1BD4; ALLOPURINOL [MART.]; CHEMBL1467; NCIOpen2_001825; Lopac0_000102; SCHEMBL25803; ALLOPURINOL [USP-RS]; ALLOPURINOL [WHO-DD]; ALLOPURINOL [WHO-IP]; BSPBio_001798; KBioGR_000550; KBioSS_000386; MLS001148183; US9138393, Allopurinol; US9144538, Allopurinol; DivK1c_000685; SCHEMBL167561; SCHEMBL626453; SPECTRUM1500108; SPBio_000056; ALLOPURINOLUM [WHO-IP]; GTPL6795; orb1225329; orb1310380; orb3025936; SCHEMBL1128219; SCHEMBL3739112; SCHEMBL5550199; SCHEMBL6034419; SCHEMBL7400319; SCHEMBL7400321; SCHEMBL7403740; Allopurinol (JP18/USP/INN); SCHEMBL28672687; SCHEMBL29693720; BDBM35440; HMS502C07; HY-B0219R; KBio1_000685; KBio2_000386; KBio2_002954; KBio2_005522; KBio3_001298; ALLOPURINOL [EP IMPURITY]; ALLOPURINOL [ORANGE BOOK]; NINDS_000685; ALLOPURINOL [EP MONOGRAPH]; BDBM181133; GLXC-07785; HMS1920A15; HMS2091G15; HMS2234M09; HMS3259K13; HMS3260E06; HMS3371I11; HMS3651O13; HMS3714L22; HMS5079O22; Pharmakon1600-01500108; ALLOPURINOL [USP MONOGRAPH]; SMSSF-0109038; HY-B0219; MSK10865; STR05189; Tox21_110082; Tox21_200922; Tox21_500102; 4-Hydroxy-pyrazolo[3,4-d]pyrimidin; AC-019; BBL009959; BDBM50016784; BDBM50140241; CCG-38916; EBC-03149; MFCD08276167; NSC755858; s1630; SBB004202; SC1118; SC2251; STK378584; STK711106; 1,2,5,7-tetraaza-5H-inden-4-ol; AKOS000267490; AKOS000269759; AKOS024255717; Tox21_110082_1; Allopurinol, xanthine oxidase inhibitor; CCG-204197; CCG-221406; CCG-266128; DB00437; FA17288; LP00102; NC00492; NSC-755858; SB10164; SDCCGSBI-0050090.P005; IDI1_000685; NCGC00015094-01; NCGC00015094-03; NCGC00015094-04; NCGC00015094-05; NCGC00015094-06; NCGC00015094-07; NCGC00015094-08; NCGC00015094-18; NCGC00015094-21; NCGC00015094-22; NCGC00091134-01; NCGC00091134-02; NCGC00091134-03; NCGC00094580-01; NCGC00094580-02; NCGC00094580-05; NCGC00188948-01; NCGC00258476-01; NCGC00260787-01; FA160361; FA162226; TS-00028; SBI-0050090.P004; DB-065332; DB-261136; DB-272461; DB-272465; DB-272466; DB-272469; A0907; A4445; EU-0100102; NS00000618; ST45179105; SW199406-4; T0692; 1,5-dihydropyrazolo[3,4-d]-pyrimidin-4-one; EN300-34144; VU0611037-1; BIM-0061756.0001; D00224; F18007; 1,5Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one; AB00173448-03; AB00173448-04; AB00173448_05; AB01274719-01; AB01274719_02; AB-323/25048497; F069190; Q412486; SR-01000075595; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 2,5-dihydro-; SR-01000075595-1; SR-05000001983-1; SR-05000001983-2; BRD-K86307448-001-16-7; BRD-K86307448-001-17-5; BRD-K86307448-001-19-1; F2173-0394; Z104486670; 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,2-dihydro- (9CI); 4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONE, 2,7-DIHYDRO-; Allopurinol, British Pharmacopoeia (BP) Reference Standard; Allopurinol, European Pharmacopoeia (EP) Reference Standard; Allopurinol, United States Pharmacopeia (USP) Reference Standard; 1,5-Dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one Synonym: Allopurinol; Allopurinol, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10; 691008-24-9; allopurinol, Zyloprim, Zyloric, Lopurin, Milurit, Progout, Atisuril, Bleminol, Uripurinol, Embarin, Foligan, Urosin, 1H-Pyrazolo[3,4-d]pyrimidin-4-ol, 315-30-0, Alositol, Anoprolin, Apulonga, Bloxanth, Caplenal, Cellidrin同义词
含有Allopurinol的产品
유유알로푸리놀정자이로릭정(알로푸리놀)ZYLORIC 300 mg COMPRIMIDOSZYLORIC 100 mg COMPRIMIDOSALOPURINOL TEVA 300 mg COMPRIMIDOS EFGALOPURINOL TEVA 100 mg COMPRIMIDOS EFGALOPURINOL TARBIS 300 MG COMPRIMIDOS EFGALOPURINOL TARBIS 100 MG COMPRIMIDOS EFGALOPURINOL SUN 300 mg COMPRIMIDOS EFGALOPURINOL SUN 100 mg COMPRIMIDOS EFGALOPURINOL STADAFARMA 300 MG COMPRIMIDOS EFGALOPURINOL STADAFARMA 200 MG COMPRIMIDOS EFG
第 1/11 页
销售Allopurinol的公司
第 1/7 页